Smartkarma's AI Co-Pilot, Smartkarma

αSK

Smartkarma's AI Co-Pilot

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>
<a href="https://smartkarma.com/entities/korro-bio-inc">Korro Bio </a>is a clinical-stage biopharmaceutical company developing a new class of genetic medicines by editing RNA, a transient approach that avoids permanent DNA modification.</li>
  <li>The company's proprietary OPERA (Oligonucleotide Promoted Editing of RNA) platform harnesses the body's natural ADAR enzymes to make precise, single-base edits to RNA transcripts to treat rare and prevalent diseases.</li>
  <li>Following a significant setback in November 2025 where its lead candidate KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD) missed efficacy targets, the company has restructured, pivoted its strategy, and secured financing to extend its cash runway into the second half of 2028.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  
Korro Bio is a clinical-stage biopharmaceutical company developing a new class of genetic medicines by editing RNA, a transient approach that avoids permanent DNA modification.
  The company's proprietary OPERA (Oligonucleotide Promoted Editing of RNA) platform harnesses the body's natural ADAR enzymes to make precise, single-base edits to RNA transcripts to treat rare and prevalent diseases.
  Following a significant setback in November 2025 where its lead candidate KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD) missed efficacy targets, the company has restructured, pivoted its strategy, and secured financing to extend its cash runway into the second half of 2028.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

United States

Korro Bio, Inc. operates as a biopharmaceutical company. The Company focuses to discover, develop, and commercialize RNA therapies informed by human genetics and disease biology to treat both rare and highly prevalent diseases. Korro Bio serves customers in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Korro Bio (KRRO US)

Primer: Korro Bio ( KRRO US) - May 2026

Korro Bio is a clinical-stage biopharmaceutical company developing a new class of genetic medicines by editing RNA, a transient approach that...

αSK

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)